We are live on ! Find out more
MSKCC

Memorial Sloan Kettering Cancer Center Portfolio holdings

AUM $24.6M
1-Year Est. Return 10.16%
This Fund
S&P 500
This Quarter Est. Return
-24.18%
1 Year Est. Return
+10.16%
3 Year Est. Return
-14.79%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$30.3M
AUM Growth
-$56.1M
Cap. Flow
-$44.6M
Cap. Flow %
-147.52%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$44M
2
CRBU icon
Caribou Biosciences
CRBU
+$497K
3
ILMN icon
Illumina
ILMN
+$184K

Sector Composition

Rank Sector Weight
1 Healthcare 33.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GDX icon
1
VanEck Gold Miners ETF
GDX
$27.4B
$20.2M 66.82%
738,500
– –
CRBU icon
2
Caribou Biosciences
CRBU
$164M
$3.31M 10.93%
609,196
-65,000
-10% -$497K
YMAB
3
DELISTED
Y-mAbs Therapeutics
YMAB
$2.89M 9.56%
191,176
– –
ORIC icon
4
Oric Pharmaceuticals
ORIC
$1.4B
$2.7M 8.92%
602,272
– –
ILMN icon
5
Illumina
ILMN
$28.4B
$1.14M 3.77%
6,360
-720
-10% -$184K
RPRX icon
6
Royalty Pharma
RPRX
$25.3B
– –
-1,128,255
Closed -$44M

Similar funds

BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM

Memorial Sloan Kettering Cancer Center's Q2 2022 Portfolio in Review

As of Q2 2022, Memorial Sloan Kettering Cancer Center held 6 positions worth $30.3M, down 65% from $86.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Memorial Sloan Kettering Cancer Center withdrew a net $44.6M in Q2 2022, closing 1 position and reducing 2 holdings. Its most notable exit was Royalty Pharma, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 67% a quarter earlier.

  • Memorial Sloan Kettering Cancer Center's biggest Q2 2022 reduction was Caribou Biosciences, cutting an estimated $497K.
  • Memorial Sloan Kettering Cancer Center fully exited Royalty Pharma in Q2 2022, selling an estimated $44M.
  • Memorial Sloan Kettering Cancer Center's ten largest holdings make up 100% of its $30.3M portfolio in Q2 2022.
  • Memorial Sloan Kettering Cancer Center opened 0 new positions and closed 1 in Q2 2022.
  • Memorial Sloan Kettering Cancer Center's portfolio value fell 65% quarter-over-quarter to $30.3M.

Based on Memorial Sloan Kettering Cancer Center's 13F filing for Q2 2022, filed 15 Aug 2022.